U.S. markets open in 5 hours 10 minutes

AbbVie Inc. (ABBV)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
116.22+0.47 (+0.41%)
At close: 4:04PM EDT

115.48 -0.70 (-0.60%)
Pre-Market: 4:17AM EDT

Sign in to post a message.
  • K
    KENNETH
    Over the last few years I have learned a great lesson investing in stocks , rule 1 , let your Winners Run , they are winners for a reason . In the early days of investing I sold my winners way to early and left way to much on the table
  • W
    Will
    Mizuho adjusts abbv's price from $126 to $128. BMO adjusts from $127 to $129. ABBV setting new high today.
  • c
    chester lipper
    with 3 approvals in June - July time frame, this may go to 125 target sooner; if atogepant approval and launch goes well, this may easily top the 129 target of BMO.
  • E
    E
    ABBV vs MRK, The reason I take ABBV over MRK is because of the management. MRK may be able to do better once it gets a new CEO but that is questionable. ABBV delivers and MRK misses by 14% or .21 cent earnings miss. Management is never taken into consideration when analyzing companies.
  • S
    Steve
    The company said it expects 2021 earnings of $12.37 to $12.57 per share.
    So this company trades at about 9 times 2021 earnings???
    Am I missing something here?
    Thanks.
  • J
    Jarryd
    Abbvie (ABBV) reported 1st Quarter March 2021 earnings of $2.95 per share. The consensus earnings estimate was $2.85 per share on revenue of $12.8 billion. The Earnings Whisper number was $2.97 per share.

    The company said it expects 2021 earnings of $12.37 to $12.57 per share. The company's previous guidance was earnings of $12.32 to $12.52 per share and the current consensus earnings estimate is $12.51 per share for the year ending December 31, 2021.
  • C
    Chris
    $SOLY conversation
    Should we just buying $ABBV since the merger then?
    Bullish
  • E
    Ed
    ABBV is part of the psychedelic stock along with JNJ (Spravato) , anyone know what product in the Psych space they're working on? Thanks and GLTA
    Bullish
  • T
    Tim
    Up 10% in the last 30 days! Love this stock! Divy coming soon with lots of upside still to come!
    Bullish
  • T
    Travis
    sold 300 shares and made $905. only held them since the day of earnings.
  • T
    Theodore
    This is a real solid investment. You can sleep well owning stock in this company.
  • T
    Tim
    Terry the short-seller riding a bad $ABBV position to financial oblivion!
  • J
    JoeBlack
    Imagine the price movement once the FDA moves forward with the ruling!
  • d
    dude
    $EVOK conversation
    Look at $abbv breaking out to the upside and $amgn moving back up. Will bring a lot of small players along too after brutal last few months in biotech pharma. Want to see more M&A also, that’s what we need as tech money shifts to healthcare.
  • s
    stocktargetadvior
    $ABBV
    Target Raised by Mizuho Securities Buy USD 126 » USD 128
    Maintains BMO Capital Markets Outperform USD 127 » USD 129
  • r
    robert
    ABBV continues to prove its best of breed status among the drug stocks, posting spectacular earnings while the rest of the drug companies disappointed. It is the best drug stock for income, followed by AMGN, and its drugs are immensely successful. The stock price stability is remarkable, as is the fact that this company's status as a value stock insulates it from inflation and rising rates. I have lost money in the growth names since February but this stock has continued to put money in my pocket both in terms of capital gains and in terms of a solid income stream. It's easy to see why Cathie Wood, Buffett, and so many other big time investors continue to like this stock. In fact, besides the obnoxious yahoo bear Terry, I have not heard one negative thing said about ABBV by anyone. The fact it is so well liked should be only further proof that institutions will continue to buy it up and drive the stock price higher. I like any stock that is popular amongst the smart money, because ultimately the smart money always prevails over the dumb money. ABBV is still very reasonably valued at these levels...the capital returns won't come over night, you have to be patient. And that dividend more than pays you to wait, just like the waiter/waitress who tops up your drinks while you're waiting for your food. It's not a question if ABBV will be trading at a much higher price in 5 years, it's how much higher it will trade. With its sizable pipeline and its continued demonstration to churn out blockbuster drug after blockbuster drug, only a fool is short this name.
  • W
    Will
    Diamond Hill Capital bought 2.15 million shares; now holds 2.6m shares
  • y
    y
    Mrk should consider buying out abbv to bulk up. It's the only reasonably priced pharma with solid pipeline. abbv stock should be able to end the year in $120s.
  • M
    Marie
    Nice beat nice dividend great company to own.
  • S
    Smitten with the Mitten
    Good day for the longs. The next couple years should be pretty decent.